WGS Stock: Price, Earnings History and SEC Filings
GeneDx Holdings Corp. (WGS) last traded at $69.06, down 2.76% on the latest session and down 4.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.01 against an analyst estimate of $-0.19, a beat of 105.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
WGS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 3, 2026 | $0.01 | $-0.19 | +105.26% |
| Mar 2026 | May 4, 2026 | $-0.28 | $-0.06 | -366.67% |
| Dec 2025 | Feb 23, 2026 | $0.14 | $0.11 | +27.27% |
| Sep 2025 | Oct 28, 2025 | $0.49 | $0.28 | +75.00% |
WGS beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How WGS reacts to earnings
Across its last 8 earnings releases, WGS moved 21.4% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-03 | After close | +4.48% |
| 2026-05-04 | After close | -49.20% |
| 2026-02-23 | Before open | +6.12% |
| 2026-01-12 | After close | -7.88% |
| 2025-10-28 | Before open | +5.21% |
| 2025-07-29 | Before open | +8.09% |
| 2025-04-30 | Before open | -42.85% |
| 2025-02-18 | Before open | +47.69% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
WGS financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $428M | -$21M | $14M | -4.9% | $-0.73 |
| 2024 | $305M | -$52M | -$34M | -17.1% | $-1.94 |
| 2023 | $203M | -$176M | -$185M | -86.8% | $-7.23 |
| 2022 | $235M | -$549M | -$326M | -233.9% | $-53.63 |
| 2021 | $212M | -$245M | -$200M | -115.6% | $-2.27 |
| 2020 | $179M | -$241M | -$117M | -134.6% | $-47,036.00 |
| 2019 | $196M | -$30M | -$31M | -15.1% | $-264,056.00 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for WGS
- 10-Q · Aug 3, 2026
- 8-K · Aug 3, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 23, 2026Shareholder vote
- 8-K · Jun 16, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · May 4, 2026
- 8-K · May 4, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 30, 2026
- 8-K · Mar 2, 2026Material agreement, Agreement terminated, New financial obligation
- 10-K · Feb 23, 2026
- 8-K · Feb 23, 2026Results of operations, Financial statements and exhibits
Insider filing activity
WGS insiders filed 6 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
WGS news
- Our Pick Of The Best AI Healthcare Stocks In November 2026Nov 1, 2026 · finance.yahoo.com
- GeneDx Holdings And 2 Other Top Healthcare StocksOct 31, 2026 · finance.yahoo.com
- GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026Oct 23, 2026 · finance.yahoo.com
- How Long Can GeneDx Keep Burning Cash?Oct 21, 2026 · trefis.com
- Sector Update: Healthcare Stocks Gain Late AfternoonOct 20, 2026 · finance.yahoo.com
- GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease DiagnosisOct 20, 2026 · finance.yahoo.com
- GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026Oct 19, 2026 · finance.yahoo.com
About GeneDx Holdings Corp.
GeneDx Holdings Corp. (WGS) is a US-listed public company on Nasdaq. The SEC classifies its business as Services-health Services. It is incorporated in DE. Its fiscal year ends in December.